InfoCons Consumer Protection informs you – Emtricitabine/Tenofovir disoproxil Krka – Package Leaflet

Before anything else

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you .

• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine ha s been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

ℹ️ 1. What Emtricitabine/Tenofovir disoproxil Krka is and what it is used for

Emtricitabine/Tenofovir disoproxil Krka contains two active substances, emtricitabine and

tenofovir disoproxil . Both of these active substances are antiretroviral medicines which are used to treat HIV infection. Emtricitabine is a nucleoside reverse transcriptase inhibitor and tenofovir is a nucleotide reverse transcriptase inhibitor. However, both are generally known as NRTIs and they work by interfering with the normal working of an enzyme (reverse transcriptase) that is essential for the virus to reproduce itself.

• Emtricitabine/Tenofovir disoproxil Krka is used to treat Human Immunodeficiency Virus 1 (HIV -1) infection in adults .
• It is also used to treat HIV in adolescents aged 12 to less than 18 years who weigh at least 35kg, and who have already been treated with other HIV medicines that are no longer effective or have caused side effects.

-Emtricitabine/Tenofovir disoproxil Krka should always be used combined with other medicines to treat HIV infection. -Emtricitabine/Tenofovir d isoproxil Krka can be administered in place of emtricitabine and tenofovir disoproxil used separately at the same doses.

This medicine is not a cure for HIV infection . While taking Emtricitabine/Tenofovir disoproxil Krka you may still develop infections o r other illnesses associated with HIV infection.

• Emtricitabine/Tenofovir disoproxil Krka is also used to reduce the risk of getting HIV -1 infection in adults ,and adolescents aged 12 years to less than 18 years who weigh at least 35 kg , when taken daily, together with safer sex practices:

See section 2 for a list of precautions to take against HIV infection.

⚠️ 2. What you need to know before you take Em tricitabine/Tenofovir disoproxil Krka

Do not take Em tricitabine/Tenofovir disoproxil Krka to treat HIV or to reduce the risk of

getting HIV if you are allergic to emtricitabine, tenofovir, tenofovir disoproxil, or any of the other ingredients of this medicine (listed in section 6).

48→ If this applies to you, tell your doctor immediately.

Before taking Em tricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV Emtricitabine/Tenofovir disoproxil Krka can only help reduce your risk of getting HIV before you are infected.

• You must be HIV negative before you start to take Em tricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV. You must get tested to make sure that you do not already have HIV infection. Do not take Emtricitabine/Tenofovir disoproxil Krka to reduce your risk unless you are confirmed to be HIV negative. People who do have HIV must take Emtricitabine/Tenofovir disoproxil Krka in combination with other drugs.
• Many HIV tests can miss a recent infection. If you get a flu -like illness, it could mean you have recently been infected with HIV. These may be signs of HIV in fection:

-tiredness -fever -joint or muscle aches -headache -vomiting or diarrhoea -rash -night sweats -enlarged lymph nodes in the neck or groin → Tell your doctor about any flu -like illness –either in the month before starting Emtricitabine/Tenofovir disoproxil Krka, or at any time while taking Emtricitabine/Tenofovir disoproxil Krka.

Warnings and precautions

While taking Emtricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV:

• Take Emtricitabine/T enofovir disoproxil Krka every day to reduce your risk, not just when you think you have been at risk of HIV infection. Do not miss any doses of Emtricitabine/Tenofovir disoproxil Krka, or stop taking it. Missing doses may increase your risk of getting HIV infection.
• Get tested for HIV reg ularly.
• If you think you were infected with HIV, tell your doctor straight away. They may want to do more tests to make sure you are still HIV negative.
• Just taking Em tricitabine/Tenofovir disoproxil Krka may not stop you getting HIV .

-Always practice safer sex. Use condoms to reduce contact with semen, vaginal fluids, or blood. -Do not share personal items that can have blood or body fluids on them, such as toothbrushes and razor blades. -Do not share or re -use needles or other injection or drug equipmen t. -Get tested for other sexually transmitted infections such as syphilis and gonorrhoea.

These infections make it easier for HIV to infect you.

Ask your doctor if you have any more questions about how to prevent getting HIV or spreading HIV to other peopl e.

While taking Emtricitabine/Tenofovir disoproxil Krka to treat HIV or to reduce the risk of getting HIV:

49- Emtricitabine/Tenofovir disoproxil Krka may affect your kidneys. Before and during treatment, your doctor may order blood tests to measure kidney function. Tell your doctor if you have had kidney disease, or if tests have shown kidney problems. Emtricitabine/Tenofovir disoproxil Krka should not be given to adolescents with existing kidney problems. If you have kidney problems, your doctor may advise you to stop taking Emtricitabine/Tenofovir disoproxil Krka or, if you already have HIV, to take Emtricitabine/Tenofovir disoproxil Krka less frequently. Emtricitabine/T enofovir disoproxil Krka is not recommended if you have severe kidney disease or are on dialysis.

• Talk to your doctor if you suffer from osteoporosis, have a history of bone fracture or if you have problems with your bones.

Bone problems (manifesting as persistent or worsening bone pain and sometimes resulting in fractures) may also occur due to damage to kidney tubule cells (see section 4, Possible side effects ).Tell your doctor if you have bone pain or fractures.

Tenofovir disoproxil may also cause loss of bone mass. The most pronounced bone loss was seen in clinical studies when patien ts were treated for HIV with tenofovir disoproxil in combination with a boosted protease inhibitor.

Overall, the effects of tenofovir disoproxil on long term bone health and future fracture risk in adult and paediatric patients are uncertain.

• Talk to you r doctor if you have a history of liver disease, including hepatitis. Patients infected with HIV who also have liver disease (including chronic hepatitis B or C), who are treated with antiretrovirals, have a higher risk of severe and potentially fatal live r complications.

If you have hepatitis B or C, your doctor will carefully consider the best treatment regimen for you.

• Know your hepatitis B virus (HBV) infection status befor e starting Emtricitabine/Tenofovir disoproxil Krka. If you have HBV, there is a serious risk of liver problems when you stop taking Emtricitabine/Tenofovir disoproxil Krka, whether or not you also have HIV. It is important not to stop taking Emtricitabine/Tenofovir disoproxil Krka without talking to your doctor: see section 3, Do not stop taking Emtricitabine/Tenofovir disoproxil Krka .
• Talk to your doctor if you are over 65. Emtricitabine/Tenofovir disoproxil Krka has not been studied in patients over 65 years of age.
• Talk to your doctor if you are intolerant to lactose (see Emtricit abine/T enofovir disoproxil

Krka contains lactose later in this section).

Children and adolescents

Emtricitabine/Tenofovir disoproxil Krka is not for use in children under 12 years of age.

Other medicines and Emtricitabine/Tenofovir disoproxil Krka

Do not take Em tricitabine/Tenofovir disoproxil Krka if you are already taking other medicines that contain the components of Emtricitabine/T enofovir disoproxil Krka (emtricitabine and tenofovir disoproxil) or any other antiviral medicines that contain teno fovir alafenamide, lamivudine or adefovir dipivoxil.

Taking Emtricitabine/Tenofovir disoproxil Krka with other medicines that can damage your kidneys: it is especially important to tell your doctor if you are taking any of these medicines, including

• amino glycosides (for bacterial infection)
• amphotericin B (for fungal infection) 50- foscarnet (for viral infection)
• ganciclovir (for viral infection)
• pentamidine (for infections)
• vancomycin (for bacterial infection)
• interleukin -2 (to treat cancer)
• cidofovir (for vi ral infection)
• non-steroidal anti -inflammatory drugs (NSAIDs, to relieve bone or muscle pains) If you are taking another antiviral medicine called a protease inhibitor to treat HIV, your doctor may order blood tests to closely monitor your kidney function .

It is also important to tell your doctor if you are taking ledipasvir/sofosbuvir, sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir to treat hepatitis C infection.

Taking Emtricitabine/Tenofovir disoproxil Krka with other medicines containing didanosine (for treatment of HIV infection): Taking Emtricitabine/Tenofovir disoproxil Krka with other antiviral medicines that contain didanosine can raise the levels of didano sine in your blood and may reduce CD4 cell counts. Rarely, inflammation of the pancreas and lactic acidosis (excess lactic acid in the blood), which sometimes causes death, have been reported when medicines containing tenofovir disoproxil and didanosine we re taken together. Your doctor will carefully consider whether to treat you with combinations of tenofovir and didanosine. → Tell your doctor if you are taking any of these medicines. Tell your doctor or pharmacist if you are taking, have recently taken o r might take any other medicines.

Emtricitabine/Tenofovir disoproxil Krka with food and drink

• Whenever possible, Emtricitabine/Tenofovir disoproxil Krka should be taken with food .

Pregnancy and breast -feeding If you are pregnant or breast -feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

If you have taken Emtricitabine/Tenofovir disoproxil Krka during your pregnancy, your doctor may request regular blood tests an d other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.

• Do not breast -feed during treatment with Emtricitabi ne/Tenofovir disoproxil Krka. This is because the active substances in this medicine pass into human breast milk.
• Breast -feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk.
• If you are bre ast-feeding, or thinking about breast -feeding, you should discuss it with your doctor as soon as possible .

Driving and using machines

Emtricitabine/Tenofovir disoproxil Krka can cause dizziness. If you feel dizzy while taking Emtricitabine/Tenofovir diso proxil Krka, do not drive and do not use any tools or machines.

Emtricitabine/Tenofovir disoproxil Krka contains lactose

If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor befor e taking this medicinal product.

51Emtricitabine/Tenofovir disoproxil Krka contains sodium

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium – free’.

💊 3. How to take Em tricitabine/Tenofovir disoproxil Krka

• Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose of Emtricitabine/Tenofovir disoproxil Krka to treat HIV is:

• Adults: one tablet each day, where possible, with food .
• Adolescents aged 12 to less than 18 years who weigh at least 35 kg:one tablet each day,

whenever possible with food

The recommended dose of Em tricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV is:

• Adults : one tablet each day, whenever possible with food.
• Adolescents aged 12 to less than 18 years who weigh at least 35 kg: one tablet each day, whenever possible with food.

If you have difficulty swallowing, you can use the tip of a spoon to crush the tablet. Then mix the powder with about 100 mL (half a glass) of water, orange juice or grape juice, and drink immediately.

• Always take the dose recommended by your doctor. This is to make sure that your medicine is fully effective, and to reduce the risk of developing resistance to the treatment. Do not ch ange the dose unless your doctor tells you to.
• If you are being treated for HIV infection your doctor will prescribe Emtricitabine/Tenofovir disoproxil Krka with other antiretroviral medicines. Please refer to the patient information leaflets of the other antiretrovirals for guidance on how to take those medicines.
• If you are taking Emtricitabine/Tenofovir disoproxil Krka to reduce the risk of getting HIV , take Emtricitabine/T enofovir disoproxil Krka every day, not just when you think you have been at ris k of HIV infection.

Ask your doctor if you have any questions about how to prevent getting HIV or prevent spreading HIV to other people.

If you take more Em tricitabine/Tenofovir disoproxil Krka than you should

If you accidentally take more than the reco mmended dose of Emtricitabine/T enofovir disoproxil Krka, contact your doctor or nearest emergency department for advice. Keep the tablet bottle with you so that you can easily describe what you have taken.

If you miss a dose It is important not to miss a dose of Emtricitabine/Tenofovir disoproxil Krka.

• If you notice within 12 hours of the time you usually take Emtricitabine/Tenofovir disoproxil Krka, take the tablet preferably with food as soon as possible. Then take the next dose at your usual time.
• If you notice 12 hours or m ore after the time you usually take Emtricitabine/Tenofovir disoproxil Krka, forget about the missed dose. Wait and take the next dose, preferably with food, at your usual time.

52If you vomit less than 1 hour after taking Em tricitab ine/Tenofovir disoproxil Krka , take another tablet. You do not need to take another tablet if you were sick more than 1 hour after taking Emtricitabine/Tenofovir disoproxil Krka.

Do not stop taking Emtricitabine/Tenofovir disoproxil Krka

• If you take Emtricitabine/Tenofovir disoproxil Krka for treatment of HIV infection , stopping tablets may reduce the effectiveness of the anti -HIV therapy recommended by your doctor.
• If you are taking Emtricitabine/Tenofovir disoproxil Krka to reduce the risk of getti ng HIV , do not stop taking Emtricitabine/Tenofovir disoproxil Krka or miss any doses. Stopping use of Emtricitabine/T enofovir disoproxil Krka, or missing doses, may increase your risk of getting HIV infection.

→ Do not stop taking Em tricitabine/Tenofovir disoproxil Krka without contacting your doctor.

If you have hepatitis B , it is especially important not to stop your Emtricitabine/Tenofovir disoproxil Krka treatment without talking to your doctor first. You may require blood tests for several months after stopping treatment. In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be life -threatening. → Tell your doctor immediately about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis B infection If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

❗ 4. Possible side effects

Like all medi cines, this medicine can cause side effects, although not everybody gets them.

Possible serious side effects:

• Lactic acidosis (excess lactic acid in the blood) is a rare but potentially life -threatening side effect. Lactic acidosis occurs more often in w omen, particularly if they are overweight, and in people with liver disease. The following may be signs of lactic acidosis:
• deep rapid breathing
• drowsiness
• feeling sick (nausea), being sick (vomiting)
• stomach pain → If you think you may have lactic acidosis, get medical help immediately.
• Any signs of inflammation or infection. In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections (infections that occur in people with a weak immune system), signs and symptoms o f inflammation from previous infections may occur soon after anti-HIV treatment is started. It is thought that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
• Autoimmune disorders , when the immune system attacks healthy body tissue, may also occur after you start taking medicines to treat HIV infection. Autoimmune disorders may occur many months after the start of treatment. Look out for any s ymptoms of infection or other symptoms such as:

-muscle weakness 53-weakness beginning in the hands and feet and moving up towards the trunk of the body -palpitations, tremor or hyperactivity → If you notice these or any symptoms of inflammation or infection, get medical help immediately.

Possible side effects:

Very common side effects

(may affect more than 1 in 10 people)

• diarrhoea, being sick (vomiting), feeling sick (nausea)
• dizziness, headache
• rash
• feeling weak Tests may also show:
• decreases in phosphate in the blood
• increased creatine kinase

Common side effects

(may affect up to 1 in 10 people)

• pain, stomach pain
• difficulty sleeping, abnormal dreams
• problems with digestion resulting in discomfort after meals, feeling bloated, flatulence
• rashes (includin g red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions, itching, changes in skin colour including darkening of the skin in patches
• other allergic reactions, such as wheezing, swelling or feeling light -headed
• loss of bone mass Tests may also show:
• low white blood cell count (a reduced white blood cell count can make you more prone to infection)
• increased triglycerides (fatty acids), bile or sugar in the blood
• liver and pancreas problems

Uncommon side effects

(may affect up to 1 in 100 people)

• pain in the abdomen (tummy) caused by inflammation of the pancreas
• swelling of the face, lips, tongue or throat
• anaemia (low red blood cell count)
• breakdown of muscle, muscle pain or weakness which may occur due t o damage to the kidney tubule cells Tests may also show:
• decreases in potassium in the blood
• increased creatinine in your blood
• changes to your urine

Rare side effects

(may affect up to 1 in 1 000 people)

• Lactic acidosis (see Possible serious side effect s)
• fatty liver
• yellow skin or eyes, itching, or pain in the abdomen (tummy) caused by inflammation of the liver
• inflammation of the kidney, passing a lot of urine and feeling thirsty, kidney failure, damage to kidney tubule cells 54- softening of the bones (with bone pain and sometimes resulting in fractures)
• back pain caused by kidney problems Damage to kidney tubule cells may be associated with breakdown of muscle, softening of the bones (with bone pain and sometimes resulting in fractures), muscle pain, muscle weakness and decreases in potassium or phosphate in the blood.

→ If you notice any of the side effects listed above or if any of the side effects get serious , talk to your doctor or pharmacist.

The frequency of the following side effects is not kn own.

• Bone problems. Some patients taking combination antiretroviral medicines such as emtricitabine/tenofovir disoproxil may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). Taking this type of medicine for a long time, taking corticosteroids, drinking alcohol, having a very weak immune system, and being overweight, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are:
• joint stiffness
• joint aches and pains (especially of the hip, knee and shoulder)
• difficulty with movement → If you notice any of these symptoms tell your doctor.

During treatment for HIV there may be an increase in weight and in levels of blood lipids and glucose.

This is partly linked to res tored hea lth and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.

Other effects in children

• Children given emtricitabine very commonly experienced changes in skin colour including
• darkening of the skin in patches
• Children commonly experienced low red blood cell count (anaemia)
• this may cause the child to be tired or breathless → If you notice any of these symptoms tell your doctor.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V .By reporting side effects you can help provide more information on the s afety of this medicine.

🌡️ 5. How to store Em tricitabine/Tenofovir disoproxil Krka

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the packaging after EXP . The expiry date refers to the last day of that month.

Blisters Do not store above 30 C.

Store in the original blister in order to protect from moisture and light.

Bottle Do not store above 30 C.

Keep the bottle tightly closed in order to protect from moisture and light.

Shelf life after first opening of the bottle: 2 months.

55Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

📦 6. Contents o f the pack and other information

What Emtricitabine/Tenofovir disoproxil Krka contains

• The active substances are emtricitabine and tenofovir disoproxil.

Each tablet contains 200mg of emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300.7 mg of tenofovir disoproxil succinate or 136 mg of tenofovir).

• The other ingredients are:

Tablet core: pregelatinized starch, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, sodium stearyl fumarate, stearic acid.

Film coating: hypromellose 5 cP, titanium dioxide (E171), macrogol, indigo carmine alum inium lake (E132). See section 2 ” Emtricitabine/Tenofovir disoproxil Krka contains lactose “, “Emtricitabine/Tenofovir disoproxil Krka contains sodium “.

What Emtricitabine/Tenofovir d isoproxil Krka looks like and contents of the pack

Emtricitabine/Tenofovir disoproxil Krka film -coated tablets (tablets) are blue, oval, biconvex tablets, of dimensions 20 mm x 10 mm.

Emtricitabine/Tenofovir disoproxil Krka is available in carton boxes of 28, 84 film -coated tablets and 28 x 1 film -coated tablet in blisters.

Emtricitabine/Tenofovir disoproxil Krka is available also in bottles of 30 tablets, with a child -resistant tamper evident plastic closure with integrated a silica gel desiccant, which helps to protect your tablets. The following pack sizes are available: outer cartons containing 1 bottle of 30 film -coated tablets and 90 (3 bottles of 30) film -coated tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

Manufacturers

KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz -Lohm ann-Straße 5, 27472 Cuxhaven, Germany For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien KRKA Belgium, SA.

Tél/Tel: + 32 (0) 487 50 73 62Lietuva UAB KRKA Lietuva Tel: + 370 5 236 27 40 България КРКА България ЕООД Teл.: + 359 (02) 962 34 50Luxembourg/Luxemburg KRKA Belgium, SA.

Tél/Tel: + 32 (0) 487 50 73 62 (BE) Česká republika KRKA ČR, s.r.o.

Tel: + 420 (0) 221 115 150Magyarország KRKA Magyarország Kereskedelmi Kft.

Tel.: + 36 (1) 355 8490 Danmark KRKA Sverige AB Tlf.: + 46 (0) 8 643 67 66 (SE)Malta E. J. Busuttil Ltd.

Tel: + 356 21 445 885 Deutschland Nederland 56TAD Pharma GmbH Tel: + 49 (0) 4721 606 -0KRKA Belgium, SA.

Tel: + 32 (0) 487 50 73 62 (BE) Eesti KRKA, d.d., Novo mesto Eesti filiaal Tel: + 372 (0) 6 671 658Norge KRKA Sverige AB Tlf: + 46 (0) 8 643 67 66 (SE) Ελλάδα BioARS Therapeutics A.E.

Τηλ: + 30 2107717598Österreich KRKA Pharma GmbH, Wien Tel:+ 43 (0)1 66 24 300 España KRKA Farm acéutica, S.L.

Tel: + 34 911 61 03 80Polska KRKA -POLSKA Sp. z o.o.

Tel.: + 48 (0)22 573 7500 France KRKA France Eurl Tél: + 33 (0)1 57 40 82 25Portugal KRKA Farmacêutica, Sociedade Unipessoal Lda.

Tel: + 351 (0)21 46 43 650 Hrvatska KRKA -FARMA d.o.o.

Tel: + 385 1 6312 101România KRKA Romania S.R.L., Bucharest Tel: + 4 021 310 66 05 Ireland KRKA Pharma Dublin, Ltd.

Tel: + 353 1 413 3710Slovenija KRKA, d.d., Novo mesto Tel: + 386 (0) 1 47 51 100 Ísland LYFIS ehf.

Sími: + 354 534 3500Slovenská republika KRKA Slovensko , s.r.o.

Tel: + 421 (0) 2 571 04 501 Italia KRKA Farm aceutici Milano S.r.l.

Tel: + 39 02 3300 8841Suomi/Finland KRKA Finland Oy Puh/Tel: + 358 20 754 5330 Κύπρος KI.PA. (PHARMACAL) LIMITED Τηλ: + 357 24 651 882Sverige KRKA Sverige AB Tel: + 46 (0) 8 643 67 66 (SE) Latvija KRKA Latvija SIA Tel: + 371 6 733 86 10

This leaflet was last revised in

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu .

📄 Package Leaflet – official source

This article reproduces the information in the official package leaflet, as authorised in the European Union. You can consult the original document here: Product information Emtricitabine/Tenofovir disoproxil Krka (PDF, ec.europa.eu).

You can check this medicine at any time in the Union Register of medicinal products (EU number EU/1/16/1151).

⚠️ Important: This article is for information purposes only and does not replace medical advice or the package leaflet inside the medicine box. Read the leaflet carefully before use. For any questions about your treatment, talk to your doctor or pharmacist. If you experience side effects, tell your doctor or pharmacist and report them through your national reporting system.